A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Pankaj B DesaiAniruddha S KarveMisam ZawitPriyanka AroraNimita DaveJoy AwosikaNingjing LiBethany FuhrmanMario MedvedovicLarry SallansAdy KendlerBiplab DasGuptaDavid R PlasRichard CurryMario ZuccarelloRekha ChaudharySoma SenguptaTrisha Michel Wise-DraperPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Based on safety, brain tumoral PK, and mechanistic data, 15 mg daily is identified as the RP2D for future trials.
Keyphrases
- high grade
- low grade
- open label
- physical activity
- electronic health record
- white matter
- current status
- resting state
- polycystic ovary syndrome
- stem cells
- clinical trial
- metabolic syndrome
- bone marrow
- skeletal muscle
- mesenchymal stem cells
- machine learning
- multiple sclerosis
- brain injury
- cerebral ischemia
- insulin resistance
- placebo controlled